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ABSTRACT
Objective: Chlamydia trachomatis infections are common in pregnant adolescents. Previous studies
have shown that treating pregnant women of all ages with erythromycin prevents transmission of
this infection to their infants. However, there are no published studies on the efficacy of aggressive
screening and treatment of C. trachomatis in pregnant adolescents. This study was undertaken to
determine if aggressive screening for C. trachomatis in pregnant adolescents and early treatment
with erythromycin can prevent complications in their newborn infants.
Methods:A group ofpregnant adolescents enrolled at Teen Pregnancy Service ofMilwaukee was
evaluated prospectively for the presence of C. trachomatis infection. Screening was performed
during the 1st and 3rd trimesters by enzyme immunoassay. Adolescents with positive enzyme
immunoassays for Chlamydia were treated with erythromycin for 10 days. Those with negative
enzyme immunoassays were enrolled as controls. All infants born to adolescents in both groups
were followed for episodes of conjunctivitis, pneumonia, and wheezing during their 1st year of life.
Results: Ninety mother/infant pairs were followed during the study period. Twenty-eight mothers
(31%) had positive enzyme assay tests and all received erythromycin therapy. Nasopharyngeal
cultures were obtained from 60 (67%) infants; all were negative. There were no significant differ-
ences in general characteristics, development of conjunctivitis (relative risk 1.27), wheezing (rela-
tive risk 0.91), or pneumonia (relative risk 1.12) between infants born to adolescents in either group.
Conclusions: We conclude that aggressive screening and treatment of C. trachomatis infection in
pregnant adolescents may prevent complications in their offspring. (C) 1994 Wiley-Liss, Inc.
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hlamydia trachomatis is a common sexually
transmitted infection among pregnant adoles-
cents; the infection rate ranges from 14 to 27%.
1-3
Infections during pregnancy are often transmitted
to the infant at the time of delivery.
4-6 Rates of
transmission vary from 50 to 75% of infants born
to infected mothers. Previous studies in women of
all childbearing ages have shown that the use of
erythromycin during pregnancy diminishes C. tra-
chomatis transmission to the infant and prevents
complications such as conjunctivitis and pneumo-
nia. 7’* Adolescents are particularly at risk for poor
compliance with prenatal care and medication ad-
ministration and for reinfection with C. trachoma-
t/S. 9-11 There are no studies that have examined the
effectiveness of erythromycin during pregnancy in
a purely adolescent population.
This prospective cohort study was undertaken to
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evaluate whether infants born to adolescents treated
for C. trachomatis with erythromycin during preg-
nancy were at increased risk for the complications
of wheezing, conjunctivitis, and pneumonia com-
pared with infants born to mothers who were nega-
tive for C. trachomatis during pregnancy.
SUBJECTS AND METHODS
During a 12-month period, all pregnant adoles-
cents presenting for prenatal care at Teen Preg-
nancy Service of Milwaukee were screened for C.
trachomatis infection. An enzyme immunoassay test
(Chlamydiazyme
TM Abbott Laboratories, North
Chicago, IL) was performed at intake, 36 weeks
gestation, and 6-8 weeks postpartum. A mother
was considered C. trachomatis positive if a chlamy-
dial enzyme immunoassay was positive during preg-
nancy. Adolescents with C. trachomatis were treated
within week of testing with erythromycin base,
500 mg t.i.d, for 10 days, and retested within
month. C. trachomatis infections detected at any
time during pregnancy were also treated with eryth-
romycin at the same dose. Prenatal testing, treat-
ment, and instruction regarding chlamydial infec-
tion were provided to all patients by a certified
nurse-midwife on a one-to-one basis. A multidisci-
plinary program supported all pregnant teens
throughout pregnancy with prenatal education
classes, social worker intervention, nutritional coun-
seling through the Women Infant Children Nutri-
tion Site (WIC), and group counseling sessions at
the same site. Sexual partners were referred for
treatment. At the time of delivery, all infants re-
ceived erythromycin ophthalmic ointment prophy-
laxis. Demographic data and smoking history were
obtained from each patient.
Infants of both C. trachomatis-positive and -neg-
ative mothers were followed prospectively for
year for episodes of conjunctivitis, pneumonia, and
wheezing. Visits were scheduled monthly for the
1st 6 months of the infant’s life and then every
other month until the 1st birthday. Conjunctivitis
was defined as erythema with drainage of or both
eyes. Pneumonia was defined as tales in conjunc-
tion with abnormal chest X-ray. Wheezing was
defined as tachypnea associated with expiratory
wheezes on auscultation. Episodes were identified
during either well-baby visits or sick visits at the
clinic or emergency department; history of eye
drainage or respiratory distress was requested from
TABLE I. General characteristics
C. trachornatis
positive
(N )
C. trachornatis
negative
(N 62)
Race
Black 23 (82%) 46 (74%)
White 3 (I I%) 6 (10%)
Other 2 (7%) 10 (16%)
Maternal age (years) 16.8 +_ 0.3 17.3 +- 0.2
Infant weight (g)a 3,149 _+ 14 3,194 -
75
No. of smokers 8 17
No. of clinic visits 10 II
0.2
0.7
0.9d
0.3
aMean -
SEM.
bTotal number of smokers in each group.
cStudent’s t-test.
dChi-squared test.
care givers at each clinic visit. Access to all medical
records for visits was assured since patients were
enrolled in a managed-care plan. Nasopharyngeal
swabs of infants in both groups were collected be-
tween and 6 months of age on Chlamydia Tran-
swab (R) (Microdiagnostics Corp., Cleveland, OH)
and sent directly to the laboratory for McCoy cell
culture during well-child visits. Infants with pneu-
monia or conjunctivitis were also cultured for C.
trachomatis at the time of their acute illness. Data
were analyzed using the Student’s t-test, chi-squared
test, and Mann-Whitney rank test. Relative risks,
with 95% confidence interval, were calculated for
outcome variables.
RESULTS
One hundred ten mother/infant pairs were enrolled
and followed during the study period. Twenty pairs
were excluded from the study due to change in care
providers and loss offollow-up ofthe infants. There
were no differences in the excluded group and the
group studied by race, smoking, age, birth weight,
or C. trachomatis status. Twenty-eight mothers were
C. trachomatis positive and 62 were C. trachomatis
negative. Estimated gestational age at intake was
17.2 weeks (range 10-27 weeks) for C. trachoma-
t/s-positive mothers and 16.9 weeks (range 11-30
weeks) for C. trachomatis-negative mothers. The
demographic characteristics for the 2 groups are
summarized in Table 1. There were no significant
differences for maternal age, race, birth weight, or
history of maternal smoking. Eighty-eight of 90
(98%) mothers were eligible for Medicaid.
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TABLE 2. Mothers with evidence of C. trachomatis during pregnancy
a
Intake
(+)
N 22
Intake
N=6
(-) ............................................. Postpartum
36 weeks (-)
N 18 N--18
(+) 20 weeks
N=I
1,
(+) Postpartum
36 weeks (-)
N=2 N=2
(-) Postpartum
36 weeks (-)
N-I
(-) Postpartum
36 weeks (+)
N=I N=I
(+) Postpartum
36 weeks (-)
N-2 N=2
(+) 20 weeks -
24 weeks 30 weeks 36 weeks Postpartum
(+) (+) (+) (-) (-)
N=I N= N=I N= N-
(+) Postpartum
36 weeks (-)
N=3 N=3
positive chlamydial enzyme immunoassay.
Chlamydial enzyme immunoassay was positive
in 22 mothers at intake. Six additional mothers
became positive for C. trachomat# during preg-
nancy. Table 2 summarizes the cervical chlamydial
enzyme immunoassay results throughout pregnancy
and postpartum.
Of" the 28 infants born to mothers treated for C.
trachomatis, 21 (75%) were cultured for C. tra-
chomatis; all were negative. Forty (64%) infants
born to C. trachomatis-negative mothers were cul-
tured; all were culture negative. There were no
positive cultures for C. trachomatis during episodes
of conjunctivitis or pneumonia.
Of the 28 infants born to mothers treated for C.
trachomatis, 12 developed conjunctivitis, 2 devel-
oped pneumonia, and 12 developed wheezing. Of
the 62 infants born to C. trachomatis-negative moth-
ers, 23 developed conjunctivitis, 6 developed pneu-
monia, and 28 developed wheezing. There was no
statistical difference between the 2 groups in the
number of episodes of upper respiratory infection,
conjunctivitis, pneumonia, or wheezing by the
Mann-Whitney rank test. Relative risk for con-
junctivitis was 1.27, for pneumonia was 1.12, and
for wheezing was 0.91 between the 2 groups (Ta-
ble 3).
DISCUSSION
The literature provides little data on the compliance
of treatment of C. trachomatis among pregnant ad-
olescents and the outcome oftheir infants. Although
compliance may be a problem for adolescents, we
found that most mothers treated early in their preg-
nancy for C. trachomatis remained disease-free
throughout pregnancy. Infants born to mothers
treated for C. trachomatis showed no evidence of
nasopharyngeal carriage nor did they have conjunc-
tivitis, pneumonia, or wheezing more frequently
than infants born to C. trachomatis-negative moth-
ers.
Adolescents, especially during pregnancy, are at
greater risk for C. trachomat# infections than adult
women. In our study, 31% of pregnant adolescents
had C. trachomatis infection. Earlier studies
1-3 have
reported an infection rate between 14 and 27%. In
another study conducted in Milwaukee, 11% of
pregnant adult women (mean age 24 years) were
found to be infected with C. trachomatis.
12 Factors
12 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYCHLAMYDIA TRACHOMATIS IN ADOLESCENTS MELZER-LANGE ET AL.
TABLE 3. Relationship between disease outcome and maternal C. trachomatis results
C. trachomatis positive
(N 28)
%%
C. trachomatis negative Relative confidence
(N 62) risk interval
Conjunctivitis 12 23
No conjunctivitis 16 39
Wheezing 12 28
No wheezing 16 34
Pneumonia 2 6
No pneumonia 26 56
1.27 0.52,3.06
0.91 0.36,2.21
1.12 0.19,6.4
which account for the high prevalence of C. tra-
chomatis in adolescents may include increased sexual
activity at an earlier age and multiple sexual part-
ners. Furthermore, pregnant adolescents may also
be more likely than nonpregnant adolescents to be
infected with C. trachomatis. In Brooklyn, NY, the
rates were 16% in pregnant adolescents compared
with 7.3% in nonpregnant adolescents. Chacko
and Lovchik
3 reported C. trachomatis rates of 27%
in pregnant teens and 23% in nonpregnant teens.
The enzyme immunoassay method was used for
the detection of C. trachomatis in the endocervical
samples from the pregnant adolescents in this study.
This method was selected because it is easy to trans-
port and the results can be obtained within day.
Though culture by McCoy cell has been the gold
standard for detection of chlamydial infection,
the enzyme immunoassay has been shown to be
appropriate for the screening of pregnant women
and adolescents. Baselski et al.
13 showed the en-
zyme immunoassay (Chlamydiazyme TM) to have a
sensitivity of 96.3 and a specificity of 92.9% com-
pared with culture in a group of pregnant women.
In a study of female adolescents, the enzyme immu-
noassay demonstrated a sensitivity of 100% and a
specificity of 88%.
14
Th timing of C. trachomatis screening and
erythromycin therapy during pregnancy is contro-
versial. Schachter et al.
7 treated pregnant patients
at 36 weeks gestation in hopes of allowing a C.
trachomat#-free genital tract at the time of delivery.
Eight of 152 infants in that study were born while
the mother was still taking erythromycin; 2 infants
developed C. trachomat# infections. Other studies
have examined the efficacy of erythromycin for
15 treatment of C. trachomatis during pregnancy.
However, the efficacy has not been examined in a
purely adolescent population.
Compliance, risk-taking behavior, multiple sex-
ual partners, and poor condom use are all factors
that may make C. trachomatis treatment in pregnant
adolescents problematic. We felt that an aggressive
approach to the eradication of C. trachomatis dur-
ing the entire gestation of an adolescent pregnancy
is appropriate. In our study, pregnant adolescents
were screened and treated at intake and again at 36
weeks gestation. Those adolescents who were posi-
tive for C. trachomatis at intake were aggressively
treated and tests of cure were performed 2 weeks
after completion of therapy. Although the use of
erythromycin during pregnancy has been reported
to be associated with poor compliance due to gas-
trointestinal side effects,
16 the adolescents in our
study reported completion of their erythromycin
course on their follow-up visits. Early testing of
pregnant teens permitted identification and treat-
ment of sexual partners. Any adolescent who re-
ported exposure during pregnancy to C. trachoma-
tis from an infected partner was also retested and
treated. In the present study, 82% of mothers
treated for C. trachomatis during the early months
of pregnancy remained negative throughout the
pregnancy. With aggressive management, C. tra-
chomatis was eradicated in an additional 14% of
teens prior to delivery. Treatment initiated at de-
tection of C. trachomatis at intake was successful in
our study and most adolescents remained negative
throughout their pregnancy. Patients negative at
intake for C. trachomatis who became infected later
in pregnancy were detected at testing at 36 weeks.
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Although current Centers for Disease Control
17
recommendations advise testing and treatment at
36 weeks, our data suggest that evaluation should
be done at both the prenatal intake and the 3rd
trimester to control chlamydial infection in adoles-
cents.
Another argument may be made to support the
recommendation for chlamydial detection early in
pregnancy. Recent studies have examined the rela-
tionship between C. trachomatis infection and pre-
mature labor and low birth weight, ls’18 Ryan et
al.
19 showed birth weights of <2,500 g in 19% of
infants of untreated C. trachomatis-positive moth-
ers vs. 11% of treated mothers. Others,
2 how-
ever, suspect that mucopurulent cervicitis, unre-
lated to C. trachomatis infection, may be a predictor
ofadverse pregnancy outcome. Erythromycin ther-
apy, unrelated to C. trachomatis infection, may also
improve birth weights; McCormack et al.
21 showed
fewer low-birth-weight infants in a group ofwomen
infected with Ureaplasma urealyticum treated with
erythromycin during the 3rd trimester. In the
present study, birth weights were not significantly
different in the 2 groups of patients.
The compliance of the pregnant teens in our
study was very good, with most presenting for care
by 20 weeks gestation and most receiving 10-11
prenatal visits. Our program offers a multidisci-
plinary approach to teen pregnancy which includes
medical, nutritional, prenatal education, pediatric
(for siblings), and social services to the pregnant
teen and her children at one inner-city site. Most
patients are referred by other adolescents and may
partly account for the initiation of care prior to the
3rd trimester. We believe that the compliance of
our pregnant adolescents may be better than what
could be attained through prenatal care at a site not
dedicated to the pregnant teen.
All cultures of infants for C. trachomatis were
negative. Cell culture by McCoy cell technique was
employed for detection of C. trachomatis in the
infants since nonculture techniques have not been
well studied in the infant population. Although no
cultures in the study infants were positive for C.
trachomatis, cultures obtained in the same manner
were positive in another group of infants during
the same time period.
Because cultures may be somewhat fastidious,
infants were followed for symptoms that could be
related to C. trachomatis infection.
13 In examining
conjunctivitis, pneumonia, and wheezing in the 2
groups, we found no differences in risk between
infants born to mothers who were C. trachomatis
negative and those born to mothers treated during
pregnancy for C. trachomatis. Although C. tra-
chomatis may be implicated in 1/3 of infants with
pneumonia,
22 we found no increase in risk for
pneumonia between the infants born to infected and
noninfected mothers. Although C. trachomatis con-
junctivitis has been found as often as 51% of the
time in young infants with conjunctivitis,
23 we
found no increase in risk for conjunctivitis between
infants born to infected and noninfected mothers.
Wheezing following C. trachomat# infection has
been reported by several authors.
24-26 Chronic C.
trachomatis infections in infants have also been re-
ported, some lasting over 2 years.
27 No evidence of
increased wheezing or chronic infection was found
in infants in the group born to mothers treated for
C. trachomatis.
The cost of screening and treatment ($84.00) of
pregnant teens is far less than the cost of outpatient
and in some cases inpatient care of infants with C.
trachomatis pneumonia. If, as suspected, C. tra-
chomatis contributes to long-term chronic respira-
tory disease in older children, further costs will
28 ensue.
CONCLUSIONS
Our study demonstrates that screening and treat-
ment for C. trachomatis in pregnant adolescents
early and throughout pregnancy may be effective in
eradicating infection and preventing infectious com-
plications in their offspring. Further studies are
needed to investigate the impact that C. trachomatis
and erythromycin have on the incidence of low
birth weight in adolescent pregnancies. Should the
newer one-dose antibiotics such as azithromycin be
found to be safe for use during pregnancy, treat-
ment may become less complicated. Programs serv-
ing pregnant teens must target C. trachomatis as a
common infection and offer early and persistent
evaluation and treatment.
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